Navigation Links
VISULAS 690s Photodynamic Therapy Laser System

ProductsVISULAS 690s Photodynamic Therapy Laser System
Company Carl Zeiss Meditec, Inc.
Item VISULAS 690s Photodynamic Therapy Laser System
Features 
  • Latest Technology: Twenty years of laser manufacturing legacy is behind the unique features of the laser to ensure safety, efficiency, and treatment accuracy.
  • Universal Slit Lamp Compatibility: Seamless integration between ZEISS and Haag-Streit slit lamps without the need of recalibration or realignment.
  • Portability: The compact and portable design facilitates growth with your expanding practice.
Description The VISULAS 690s is the benchmark for photodynamic therapy. As the instrument of choice for the international phase III Visudyne clinical trials, Carl Zeiss has leveraged its 20 year legacy in laser manufacturing to create the photodynamic therapy laser trusted by the world's leading ophthalmologists.
Info Carl Zeiss Meditec, Inc.Call Carl Zeiss Meditec, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-407-6044

Customer Service: 877-486-7473
Web site: http://www.meditec.zeiss.com/

Related medicine products :

1. VISULAS 532s
2. VISULAS YAG III Laser Capsulotomy Systems
3. VISULAS YAG III Combi Complete Laser Therapy System
4. Activa Therapy System
5. VNS Therapy System
6. Cold Shoulder™ Therapy Wrap
7. InterStim Therapy -- Sacral Nerve Stimulation (SNS) for Urinary Control
8. Osbon ErecAid Vacuum Therapy System - Automatic
9. Osbon ErecAid Vacuum Therapy System - Manual
10. Osbon ErecAid Vacuum Therapy System - Classic
11. ErecAid® Esteem™ External Vacuum Therapy System
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches.
Duckbill. 3.5 mm tip. Light curve.
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle.
2 mm curved tip. Round handle. Designated most popular model or size.
Medicine Products:
(Date:7/25/2008)...fense and Federal Agencies in, the execution of O...is a, four-day, multi-agency collaborative train...ocal agencies with large and complex incident resp...ad-hoc, secure mobile communications infrastruct..., Va., July 25 /PRNewswire/ -- Dataline LLC is ple...
(Date:7/25/2008)... J. Reilly, Joins Aethon Team, PITTSBURGH, July 2...com ), the leading developer of mobile robotics fo... that Robert J. Reilly has,joined the company as S... Reilly, who was most recently Vice President -- G...y Pharmacy Division, brings more than 30,years of ...
(Date:7/25/2008)...e presented at Fenway Park ...swire/ -- CVS/pharmacy announced today,that this y...n just 21 days,through its annual in-store fundrai...h year of the annual fundraising effort which, to ...earch. This year,s fundraiser took,place in CVS/ph...
(Date:7/25/2008)...rop pounds, study finds , , FRIDAY, July...day morning weigh-ins knows this unalterable truth...searchers have some science to back up dieters, co...people do eat more on the weekend, even when they,...s can wreak havoc on weight control, either causin...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...hat a natural compound found in blueberries, tea, ...y , and that its effects further increase when com... at by the researchers is epicatechin, one of a gr...that has been shown previously to improve cardiova...
...dispensable defence against the development and sp... TB Partnership announced today that its drug sup...ti-TB drug treatments for 10 million people to 78 ...his is an important milestone, because getting ant...
...roken families continues to take a heavy toll. The...lf and her three children has sent shockwaves acr...anged three of her small daughters and herself in ...d sashes, authorities said Tuesday. A fourth child...
...de a surprising solution to the problem of separat... and pave a new way of producing nanoscale electro...y American researchers has revealed. As part of t... Lieber of Harvard University, and Anyuan Cao of t...
Other Medicine News:Health News:Natural Compound in Grapes, Tea and Cocoa Helps to Enhance Memory 2Health News:Stop TB Partnership Has Provided Treatments for Ten Million People in Six Years 2Health News:Mother Hangs Herself and Three Children in Texas 2
(Date:7/22/2008)...rom a multi-center 293-patient European, trial -,...ge Symbol: CYT, MONTREAL, July 22 /PRNewswire-Fir...l leader in cryotherapy products to treat cardiac,...ly presented from three,European study centers usi...re published earlier today in the Journal of the A...
(Date:7/22/2008)...ty and Efficacy of Treating Patients with ...SCO, and YONGIN-SI, South Korea, July 22 /PRNewswi...a, Ontario), and its South,Korean partner Green Cr...m,a Phase I clinical trial of its first-in-class l...as well-tolerated and resulted in clear,anti-cance...
(Date:7/22/2008)..., July 22 /- Hyperion,Therapeutics, I...enrollment,in its Phase 1/2 clinical trial to eval...ng effects of HPN-100 (formally called GT4P) versu...with urea cycle disorders,(UCD). The company plans...r,of this year., (Logo: http://www.newscom.com/c...
(Date:7/22/2008)...uly 22 /- NicOx S.A.,(Euron...y completed the,enrollment of 417 osteoarthritis (...linical pharmacology studies in the United States,...e trials are designed to assess the,blood pressure...n and,naproxen, using the Ambulatory Blood Pressur...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3NSF International Acquires David Begg Associates 460 1NSF International Acquires David Begg Associates 460 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 456 1Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 456 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 456 3Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 456 4Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 456 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 224 1Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 224 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 224 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 224 44 000 e Books now available on ScienceDirect 314 14 000 e Books now available on ScienceDirect 314 2
.../PRNewswire/ -- Results from analyses,looking at...,ulcerative colitis (UC), were presented at Digest...studies were funded by Procter &,Gamble (P&G) Ph...r new information on improvement of quality of lif...mine), which is from a class,of agents known as ...
... 2007 /PRNewswire/ -- A three-year,follow-up sub...clinical trial at EuroPCR 2007 showed that the CYP...lts comparable to coronary,artery bypass graftin...han bare metal stents (BMS) in diabetic patients w..., The CYPHER(R) Stent results in the diabetic po...
Other Medicine Technology:Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 2Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 3Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 4Separate Sets of Research Show Treatment Improved Quality of Life,in as Early as Three Weeks; Patient Adherence to Medication is,Multifactorial 5Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 2Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 3Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,Disease 4